Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

References

• World Health Organization Obesity and overweight Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html Accessed March 15, 2014
   Google Scholar
• Cecchini M Sassi F Lauer JA Lee YY Guajardo-Barron V Chisholm D Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness Lancet 2010 376 9754 1775 1784 21074255
   PubMed Web of Science ®Google Scholar
• Heal DJ Gosden J Smith SL Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Br J Clin Pharmacol 2009 68 6 861 874 20002080
   PubMed Web of Science ®Google Scholar
• Jindal A Brietzke S Sowers JR Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors Cardiorenal Med 2012 2 4 314 327 23380694
   PubMed Web of Science ®Google Scholar
• Phung OJ Scholle JM Talwar M Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 2010 303 14 1410 1418 20388897
   PubMed Web of Science ®Google Scholar
• Mather A Pollock C Glucose handling by the kidney Kidney Int Suppl 2011 120 S1 S6 21358696
   PubMed Web of Science ®Google Scholar
• Zhang L Feng Y List J Kasichayanula S Pfister M Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes Obes Metab 2010 12 6 510 516 20518806
   PubMed Web of Science ®Google Scholar
• List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009 32 4 650 657 19114612
   PubMed Web of Science ®Google Scholar
• Bailey CJ SGLT2 inhibitors: glucuretic treatment for type 2 diabetes Br J Diabetes Vasc Dis 2010 10 4 193 199
   Google Scholar
• Bailey CJ Renal glucose reabsorption inhibitors to treat diabetes Trends Pharmacol Sci 2011 32 2 63 71 21211857
   PubMed Web of Science ®Google Scholar
• Grempler R Thomas L Eckhardt M Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 2012 14 1 83 90 21985634
   PubMed Web of Science ®Google Scholar
• Thomas L Grempler R Eckhardt M Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats Diabetes Obes Metab 2012 14 1 94 96 21985693
   PubMed Web of Science ®Google Scholar
• Dickinson K North TJ Anthony DM Jones RB Heal DJ Evaluation of a simplified cafeteria model for the induction of insulin resistant obesity in rats Int J Obes 1998 22 Suppl 3 S19
   Google Scholar
• Fisas A Codony X Romero G Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats Br J Pharmacol 2006 148 7 973 983 16783408
   PubMed Web of Science ®Google Scholar
• Vickers SP Jackson HC Cheetham SC The utility of animal models to evaluate novel anti-obesity agents Br J Pharmacol 2011 164 4 1248 1262 21265828
   PubMed Web of Science ®Google Scholar
• Häring HU Merker L Seewaldt-Becker E Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 2013 36 11 3396 3404 23963895
   PubMed Web of Science ®Google Scholar
• Kovacs CS Seshiah V Swallow R Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab Epub 8 1 2013
   PubMed Web of Science ®Google Scholar
• Dickinson K Mody N Slater N The effect of chronic administration of sibutramine on body composition in dietary-induced, obese female Wistar rats – an evaluation of the Foss FoodScan™ analyser 2008 Available from: http://pa2online.org/abstract/abstract.jsp?abid=29118 Accessed March 15, 2014
   Google Scholar
• Dennis EA Dengo AL Comber DL Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults Obesity (Silver Spring) 2010 18 2 300 307 19661958
   PubMed Web of Science ®Google Scholar
• James WP Caterson ID Coutinho W Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N Engl J Med 2010 363 10 905 917 20818901
   PubMed Web of Science ®Google Scholar
• Hansen HH Hansen G Tang-Christensen M The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant Eur J Pharmacol 2010 636 1–3 88 95 20385125
   PubMed Web of Science ®Google Scholar
• Bray GA Ryan DH Gordon D Heidingsfelder S Cerise F Wilson K A double-blind randomized placebo-controlled trial of sibutramine Obes Res 1996 4 3 263 270 8732960
   PubMedGoogle Scholar
• Gokcel A Gumurdulu Y Karakose H Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity Diabetes Obes Metab 2002 4 1 49 55 11874442
   PubMed Web of Science ®Google Scholar
• Sjöström L Rissanen A Andersen T Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients Lancet 1998 352 9123 167 172 9683204
   PubMed Web of Science ®Google Scholar
• Jackson HC Dickinson K Jones RB Schumacher C Jensen C Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary-induced obese rats Poster presented at: Society for Neuroscience Meeting October 23–27, 2004 San Diego, CA
   Google Scholar
• Svendsen M Helgeland M Tonstad S The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome J Hum Nutr Diet 2009 22 1 55 63 19192027
   PubMed Web of Science ®Google Scholar
• Fonseca V Effect of thiazolidinediones on body weight in patients with diabetes mellitus Am J Med 2003 115 Suppl 8A 42S 48S 14678865
   PubMed Web of Science ®Google Scholar
• Dridi S Taouis M Adiponectin and energy homeostasis: consensus and controversy J Nutr Biochem 2009 20 11 831 839 19716279
   PubMed Web of Science ®Google Scholar
• Rodríguez A Catalán V Becerril S Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats Life Sci 2008 83 15–16 540 549 18761357
   PubMed Web of Science ®Google Scholar
• Fujimori Y Katsuno K Nakashima I Ishikawa-Takemura Y Fujikura H Isaji M Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J Pharmacol Exp Ther 2008 327 1 268 276 18583547
   PubMed Web of Science ®Google Scholar
• Lloret-Linares C Greenfield JR Czernichow S Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review Diabet Med 2008 25 10 1142 1150 19046191
   PubMed Web of Science ®Google Scholar
• Jackson HC Bearham MC Hutchins LJ Mazurkiewicz SE Needham AM Heal DJ Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat Br J Pharmacol 1997 121 8 1613 1618 9283694
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren Ö Kullberg J Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin Clin Endocrinol Metab 2012 97 3 1020 1031
   Google Scholar
• Ferrannini E Berk A Hantel S Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 2013 36 12 4015 4021 24186878
   PubMed Web of Science ®Google Scholar
• Musso G Gambino R Cassader M Pagano G A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials Ann Med 2012 44 4 375 393 21495788
   PubMed Web of Science ®Google Scholar